Sign in with Google
bullish
Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition
409 Views02 Oct 2024 14:45
SUMMARY
- Dr Lal PathLabs Ltd (DLPL IN) has maintained its 10% revenue growth target for the current financial year, mainly driven by 6–7% growth in patient volume.
- The operating environment is becoming conducive. Competitive intensity in terms of predatory pricing, promotional offer, and cash burning to acquire customers, have come to an end.
- As of Q1FY25, DLPL has net cash position of INR10B. The company is looking for small or mid-sized acquisitions in South and West India and expanding in small towns.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Errors in Local Street's Projections for the KOSPI 200 Rebalancing
- Nikkei 225 Sep25 Rebal: One ADD, One DELETE Still Probable, Kokusai a Question but $3bn+ a Side
- KOSPI200 Index Rebalance Preview: 7 Changes a Side for June
- CSI300 Index Rebalance Preview: 8 Changes a Side in June; US$4.5bn Trade
- [Quiddity Index] MV Jr-Gold Miners Jun25 Leaderboard: Flow Expectations
Top Unpaywalled Insights
More »- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
- The Evolution of Portfolio Management: Bridging Traditional Models and Machine Learning
- Fractured Markets: Economic Consequences of the 2025 Tariffs
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- APAC Healthcare Weekly (Oct 20)- Eisai, Daiichi Sankyo, Junshi Bioscience, Akeso, Celltrion, Neuren19 Oct 2024
- APAC Healthcare Weekly (Oct 13)- CSPC Pharma, Hugel, Astellas, Ono Pharma, and Hanmi Pharm12 Oct 2024
- APAC Healthcare Weekly (Oct 6)-Strong Yen Impact, Sigma's Remedial Measures, Mesoblast's Fund Raise05 Oct 2024
- Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition02 Oct 2024
- Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook11 Jul 2023
- Dr Lal PathLabs (DLPL IN): Q2FY23 Review- Volume Driven Sales Growth; Sequential Margin Improvement10 Nov 2022
- Dr Lal PathLabs Ltd (DLPL IN): Base Business Recovering; Competition Is the Only Headwind26 May 2022
x